Importance of hormone receptor and HER2/HER3 status verification in preclinical breast cancer models using immunodeficient and humanized mice

被引：0
|
作者：
Kahkonen, Tiina
Suominen, Mari, I
Maki-Jouppila, Jenni
Halleen, Jussi M.
Tanaka, Azusa
Seiler, Michael
Haapaniemi, Teppo
Bernoulli, Jenni
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B099
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis
    Kahkonen, Tiina E.
    Suominen, Man I.
    Halleen, Jussi M.
    Maki-Jouppila, Jenni H.
    Tanaka, Azusa
    Seiler, Michael
    Haapaniemi, Teppo
    Bernoulli, Jenni
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Quantification of HER2/HER3 Dimerisation Status in Primary Invasive Breast Cancer
    Barros, F. F. T.
    Abdel-Fatah, T. M. A.
    Rakha, E. A.
    Chan, S.
    Green, A. R.
    Ellis, I. O.
    JOURNAL OF PATHOLOGY, 2012, 228 : S14 - S14
  • [3] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Jayanthan, Harikrishna Sekar
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Sheehan, Jonathan H.
    Koch, James P.
    Sudhan, Dhivya R.
    Brewer, Monica Red
    Servetto, Alberto
    He, Jie
    Miller, Vincent A.
    Lalani, Alshad S.
    Meiler, Jens
    Arteaga, Carlos L.
    CANCER RESEARCH, 2020, 80 (04)
  • [4] Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
    Goncalves, Juliana Pereira Lopes
    Bollwein, Christine
    Noske, Aurelia
    Jacob, Anne
    Jank, Paul
    Loibl, Sibylle
    Nekljudova, Valentina
    Fasching, Peter A. A.
    Karn, Thomas
    Marme, Frederik
    Mueller, Volkmar
    Schem, Christian
    Sinn, Bruno Valentin
    Stickeler, Elmar
    van Mackelenbergh, Marion
    Schmitt, Wolfgang D. D.
    Denkert, Carsten
    Weichert, Wilko
    Schwamborn, Kristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [5] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
  • [6] Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
    Osipo, Clodia
    Meeke, Kathleen
    Cheng, Dong
    Weichel, Alyssa
    Bertucci, Anne
    Liu, Hong
    Jordan, V. Craig
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 30 (02) : 509 - 520
  • [7] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [8] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
    Zhaomei Mu
    Teresa Klinowska
    Xiaoshen Dong
    Emily Foster
    Chris Womack
    Sandra V Fernandez
    Massimo Cristofanilli
    Journal of Experimental & Clinical Cancer Research, 33
  • [9] AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
    Mu, Zhaomei
    Klinowska, Teresa
    Dong, Xiaoshen
    Foster, Emily
    Womack, Chris
    Fernandez, Sandra V.
    Cristofanilli, Massimo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
  • [10] CLINICAL IMPORTANCE OF DISCORDANCE IN HORMONE RECEPTOR AND HER2/NEU STATUS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER
    Ustaalioglu, B. B. Oven
    Vardar, F. Aker
    Bilici, A.
    Gurleyik, G.
    Erkol, B.
    Kefeli, U.
    ANNALS OF ONCOLOGY, 2014, 25
12345